Eli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho's Jared Holz
CNBC’s Melissa Lee and Jared Holz, Mizuho Securities America healthcare sector strategist, join 'Squawk on Street' to discuss the weight-loss drug market, why he believes Eli Lilly and Novo Nordisk will remain the frontrunners for the next 2-3 years, and more.
Видео Eli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho's Jared Holz канала CNBC Television
Видео Eli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho's Jared Holz канала CNBC Television
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
'Very dangerous' for traders to hold short positions on Japanese Yen right now, says BK's Kathy LienOpening Bell, November 4, 2022AI impact: How technology and UX innovation impacts the travel industryHow tech diffuses into retailBreaking down shares of Hilton, Expedia and Match GroupNow is a time to own growth and sell some, says T. Rowe's Sebastien PageCarnival stock climbs after earnings surpriseThe underlying economy continues to hold up, says Solus' Dan GreenhausETF Edge, June 24, 2024Lockheed Martin sees record order volume in 2022 as earnings beat estimatesAFT President on using AI in the classroom: The human can never be substituted by the machineCramer’s Stop Trading: Alnylam PharmaPullback in 'salty snack' stocks due to consumer economizing, says BofA's Bryan SpillaneBusinesses need to be wary of cyber risks from vendors, says Fortalice Solutions CEO Theresa PaytonRichard: Energy transition metals are experiencing more demand than supplyThe small cap connection between big cap and growthClean Start: This clean-tech startup transforms carbon emissions into vodkaSkylar Capital Management's Bill Perkins talks natural gas prices pulling backCatalyst for small caps will be earnings growth, says Essex Investment's Nancy PrialFunction announces $53 million fundingWoods: Some frothiness in semiconductors but not the overall market